爱朋医疗(300753) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥102,316,781.63, representing a 175.44% increase compared to ¥37,146,726.16 in the same period last year[8] - Net profit attributable to shareholders was ¥19,258,855.13, up 117.06% from ¥8,872,599.72 year-on-year[8] - The net profit after deducting non-recurring gains and losses reached ¥18,778,459.93, a significant increase of 390.58% compared to ¥3,827,824.95 in the previous year[8] - The basic earnings per share for the period was ¥0.1833, reflecting a 116.92% increase from ¥0.0845 in the same quarter last year[8] - The company achieved operating revenue of ¥102,316,781.63, a year-on-year increase of 175.44% due to the resumption of business activities after COVID-19 disruptions[19] - Net profit attributable to shareholders reached ¥19,258,855.13, up 117.06% compared to the same period last year[19] - The company reported a net profit of ¥270,991,040.43 as of March 31, 2021, compared to ¥254,775,601.57 at the end of 2020, indicating an increase of about 6.5%[45] - The company reported a total comprehensive income of ¥19,691,763.50, up from ¥8,872,599.72 in the previous period, indicating a growth of approximately 121%[49] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥815,484,780.95, a decrease of 1.42% from ¥827,239,473.77 at the end of the previous year[8] - Current assets totaled ¥494,845,679.01, down from ¥523,295,787.76, indicating a decrease of about 5.4%[40] - Cash and cash equivalents decreased to ¥270,169,579.52 from ¥388,558,373.95, representing a decline of approximately 30.4%[40] - Accounts receivable increased to ¥88,045,709.59 from ¥79,228,290.34, showing an increase of about 11.5%[40] - Total current liabilities decreased to ¥46,716,755.05 from ¥85,238,417.14, a reduction of approximately 45.1%[41] - Total non-current liabilities rose to ¥5,892,537.52 from ¥2,160,861.74, an increase of about 172.5%[41] - The company's equity attributable to shareholders increased to ¥762,072,392.50 from ¥739,520,007.37, reflecting a growth of approximately 3.0%[42] - Total assets amounted to CNY 827,239,473.77, a slight decrease from CNY 831,279,623.68[62] Cash Flow - The net cash flow from operating activities was negative at -¥45,806,338.66, worsening by 98.53% compared to -¥23,073,185.78 in the same period last year[8] - Cash inflows from operating activities totaled ¥87,888,057.81, compared to ¥53,867,919.21 in the previous period, representing an increase of about 63.1%[53] - The net cash flow from operating activities was -45,806,338.66 CNY, compared to -23,073,185.78 CNY in the previous period, indicating a decline in operational cash generation[54] - Total cash outflow from operating activities amounted to 133,694,396.47 CNY, up from 76,941,104.99 CNY year-over-year[54] - The net cash flow from investing activities was -72,486,370.77 CNY, compared to -29,134,619.46 CNY in the previous period, reflecting increased investment expenditures[54] - Cash and cash equivalents at the end of the period were 270,169,579.52 CNY, down from 368,432,661.91 CNY in the previous year[55] Research and Development - The company’s R&D expenses increased by 34.70% to ¥5,755,136.68, reflecting a recovery in R&D activities after pandemic-related disruptions[18] - The company launched new products, including an anesthesia depth monitor and disposable non-invasive EEG sensors, contributing to new revenue growth[19] - The company obtained 4 invention patents, 1 utility model patent, and 6 design patents during the reporting period, enhancing its intellectual property portfolio[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,503[11] - The largest shareholder, Wang Ningyu, holds 36.15% of the shares, with 9,849,800 shares pledged[11] - A total of 497.25 million restricted shares were granted to 250 incentive recipients during the first extraordinary shareholders' meeting of 2021[26] Investments and Collaborations - The company has allocated CNY 5,818.1 million (37.39%) for the industrial base upgrade project, with CNY 1,200.28 million invested to date[29] - The R&D center construction project has received CNY 2,264.25 million (21.10%) of its CNY 10,732.61 million budget, with CNY 457.8 million invested so far[29] - The company is collaborating with the University of Sydney's China Center to develop edge intelligence analysis algorithms for pain detection in anesthesia devices[24] - The company invested CNY 25 million in Tianfeng Capital equity investment fund to explore quality projects in the industry[26] Compliance and Audit - As of March 31, 2021, the company has not experienced any overdue commitments from major stakeholders[27] - The company has not reported any non-compliance issues regarding external guarantees during the reporting period[32] - The company has not undergone an audit for the first quarter report[68]